Skip to main content
OpenTrials

Clinical trial condition

Uterine Neoplasms

Explore clinical trials studying Uterine Neoplasms. Study availability and eligibility vary by location and protocol.

2,256 public trials 565 recruiting studies
Refine in advanced search Browse all conditions

Uterine Neoplasms trial results

Completed

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

NCT00190697

Conditions
Adnexal Diseases, Breast Cancer, Breast Diseases, +22 more
Locations
  • For information regarding investigative sites for this clinical trial, call 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or contact your personal physician Houston, Texas, United States
View Trial Details
Completed

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

NCT00028405

Conditions
Adnexal Diseases, Anus Diseases, Anus Neoplasms, +54 more
Locations
  • University of Arizona, VA Medical Center Tucson, Arizona, United States
  • Detroit Medical Center, Wayne State University Detroit, Michigan, United States
  • East Carolina State University, Brody School of Medicine Greenville, North Carolina, United States
  • University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT04491942

Conditions
Adenoma, Adnexal Diseases, Advanced Bile Duct Carcinoma, +72 more
Locations
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York, United States
View Trial Details
Active, Not Recruiting

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144

Conditions
Adnexal Diseases, Breast Carcinoma, Breast Diseases, +70 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer

NCT02595879

Conditions
Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma, +23 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • Keck Medical Center of USC Pasadena Pasadena, California, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612

Conditions
Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, +30 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro Jonesboro, Arkansas, United States
View all 397 locations
View Trial Details
Active, Not Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +21 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
View all 296 locations
View Trial Details

Related conditions